By Counterforce Health Team in Orladeyo (berotralstat) —

A Real Orladeyo (Berotralstat) Approval Story with Blue Cross Blue Shield Illinois: From Denial to Coverage

Answer Box: Getting Orladeyo Covered by BCBS Illinois

Eligibility: Blue Cross Blue Shield of Illinois covers Orladeyo (berotralstat) with prior authorization for HAE prophylaxis in patients ≥12 years with confirmed diagnosis and documented attack history.

Fastest path: Submit the Illinois Uniform Prior Authorization Form with C1-INH labs, attack logs, and specialist letter to Prime Therapeutics at 877-243-6930. Decision in 15 business days (24 hours if urgent).

Start today: Call your HAE specialist to request clinical documentation and lab results (C4, C1-INH antigen/function). If denied, you have 60 days to appeal internally and 4 months for external review through Illinois Department of Insurance.

Table of Contents

Patient Profile: Sarah's HAE Journey

Sarah, a 28-year-old teacher from Chicago, had been living with hereditary angioedema (HAE) for over a decade. Her attacks—painful swelling of her face, throat, and abdomen—occurred 3-4 times monthly, forcing her to miss work and live in constant fear of a life-threatening airway episode.

Her medical history included:

  • Confirmed HAE Type I diagnosis at age 16
  • Low C4 (8 mg/dL; normal 16-47) and reduced C1-INH function (35%; normal >68%)
  • Previous trials of Cinryze (IV C1-INH) - discontinued due to difficult IV access
  • Current treatment: icatibant injections for acute attacks only
  • Insurance: Blue Cross Blue Shield of Illinois (BCBSIL) through her school district

Sarah's allergist, Dr. Mary Tobin at Northwestern, recommended Orladeyo as oral prophylaxis to reduce her attack frequency. The goal: prevent attacks rather than just treating them after they started.

Pre-Authorization Preparation

Dr. Tobin's office knew that specialty drugs like Orladeyo require thorough documentation for BCBS Illinois approval. Here's what they gathered:

Essential Documentation Checklist

  • Recent lab results (within 6 months):
    • C4 level: 8 mg/dL (clearly below normal)
    • C1-INH antigen: 12 mg/dL (reduced)
    • C1-INH functional assay: 35% (significantly reduced)
  • Attack diary showing frequency, severity, and impact on daily life
  • Prior therapy documentation: Cinryze trial records and discontinuation reason
  • Specialist consultation notes confirming HAE diagnosis and treatment plan

Medical Necessity Letter Key Points

Dr. Tobin's letter emphasized:

  1. Confirmed HAE diagnosis with supporting lab values
  2. Significant disease burden (3-4 attacks monthly affecting work/quality of life)
  3. Previous prophylaxis failure (Cinryze discontinued due to access issues)
  4. Clinical rationale for oral prophylaxis per FDA labeling
  5. Expected outcomes based on APeX-2 trial data showing 44% attack reduction
Tip: HAE specialists familiar with insurance requirements often have template letters that reference payer-specific criteria and current guidelines.

Initial Submission Process

Sarah's case was submitted through BCBS Illinois's standard prior authorization pathway:

Step-by-Step Submission

  1. Form completion: Illinois Uniform Prior Authorization Form filled out completely
  2. Clinical documentation attached: Lab reports, attack diary, specialist letter
  3. Submission method: Faxed to Prime Therapeutics at 877-243-6930
  4. Tracking: Called 800-285-9426 after 3 days to confirm receipt
  5. Timeline: Standard 15 business days for determination

The submission packet included 12 pages of supporting documentation, making a comprehensive case for medical necessity.

The Denial and Why It Happened

Ten days later, Sarah received the denial letter. The reason cited: "Insufficient documentation of previous prophylactic therapy trials."

What went wrong:

  • The denial letter referenced BCBS's requirement for "documented trial and failure of at least one other prophylactic therapy"
  • While Sarah had tried Cinryze, the records didn't clearly show it was used for prophylaxis (rather than on-demand treatment)
  • The documentation focused on access issues rather than clinical efficacy or tolerability

This is where many patients give up, but Sarah's team knew this was appealable with better documentation.

Building the Appeal

With 60 days to file an internal appeal, Dr. Tobin's office immediately began gathering additional evidence:

Enhanced Documentation Package

  1. Clarified Cinryze history: Updated letter specifying it was prescribed for prophylaxis, not acute treatment
  2. Comparative analysis: Referenced World Allergy Organization guidelines showing Orladeyo as appropriate first-line prophylaxis
  3. Quality of life impact: Detailed work absence records and functional assessment scores
  4. Peer-reviewed evidence: APeX-2 trial results showing significant attack reduction

The Appeal Letter Strategy

The appeal directly addressed the denial reason:

  • Opening paragraph: "This appeal provides additional documentation clearly establishing that the patient has tried prophylactic therapy as required by BCBS policy"
  • Point-by-point rebuttal: Each denial criterion addressed with specific evidence
  • Policy alignment: Referenced BCBS's own medical policy language supporting coverage

Counterforce Health specializes in exactly this type of targeted appeal, helping patients and providers turn insurance denials into evidence-backed approvals by identifying the specific denial basis and crafting point-by-point rebuttals aligned to each payer's own rules.

Resolution and Approval

The internal appeal was submitted via fax with delivery confirmation. Twelve days later (within the 15-business-day timeline), Sarah received approval.

Approval terms:

  • Coverage: Orladeyo 150 mg daily approved for 12 months
  • Quantity limit: 30 capsules per 30 days
  • Pharmacy: Specialty pharmacy network required
  • Reauthorization: Required annually with attack frequency documentation

What Made the Difference

  1. Specific documentation addressing the exact denial reason
  2. Clear prophylaxis history with appropriate clinical context
  3. Guideline support from recognized HAE treatment guidelines
  4. Specialist advocacy from an experienced HAE physician

Sarah started Orladeyo within a week of approval and experienced a 60% reduction in attack frequency over the following six months.

What We'd Do Differently

Looking back, here are the key lessons from Sarah's case:

Initial Submission Improvements

  • More detailed prior therapy documentation from the start
  • Explicit prophylaxis language in all clinical notes
  • Baseline attack frequency quantification with specific dates and severity scores

Process Optimization

  • Peer-to-peer review request could have expedited initial approval
  • Expedited review might have been appropriate given frequent attacks
  • Specialty pharmacy coordination earlier in the process
From our advocates: We often see HAE cases approved faster when the initial submission includes a clear timeline showing prophylaxis attempts, specific attack reduction goals, and references to the patient's individual Blue plan's medical policy. The key is addressing payer-specific criteria upfront rather than waiting for denial.

Templates and Checklists

Pre-Authorization Checklist for Orladeyo

  • Confirmed HAE diagnosis with genetic testing or biochemical markers
  • Recent C4, C1-INH antigen, and C1-INH functional assay results
  • Attack diary with frequency, severity, and functional impact
  • Documentation of previous prophylactic therapy trials
  • Specialist consultation notes supporting oral prophylaxis
  • Completed Illinois Uniform Prior Authorization Form
  • Patient insurance verification and formulary check

Appeal Documentation Checklist

  • Original denial letter with specific reasons
  • Point-by-point rebuttal addressing each denial criterion
  • Additional clinical evidence addressing gaps
  • Peer-reviewed literature supporting treatment choice
  • Updated specialist letter with enhanced rationale
  • Patient impact statement or quality of life assessment

Key Contact Information

  • BCBS Illinois Prior Auth: 800-285-9426
  • Prime Therapeutics Fax: 877-243-6930
  • Illinois Department of Insurance: 877-527-9431
  • External Review Forms: Illinois DOI website

FAQ: Common Questions

Q: How long does BCBS Illinois prior authorization take for Orladeyo? A: Standard determinations are made within 15 business days. Expedited reviews (for urgent cases) are decided within 24 hours.

Q: What if Orladeyo isn't on my BCBS Illinois formulary? A: You can request a formulary exception with documentation showing medical necessity and failure of formulary alternatives.

Q: Can I appeal if my initial prior authorization is denied? A: Yes. You have 60 days to file an internal appeal, and if that's denied, 4 months to request external review through the Illinois Department of Insurance.

Q: Do I need genetic testing for Orladeyo approval? A: Not typically. C4, C1-INH antigen, and C1-INH functional assays are usually sufficient for HAE diagnosis and prior authorization.

Q: What's the difference between internal and external appeals in Illinois? A: Internal appeals are reviewed by BCBS Illinois. External reviews are conducted by independent physicians through the Illinois Department of Insurance and are binding on the insurer.

Q: How much does Orladeyo cost with BCBS Illinois coverage? A: Costs vary by plan, but with prior authorization, you'll pay your plan's specialty drug copay or coinsurance. BioCryst offers patient assistance programs that may further reduce costs.

For patients navigating complex prior authorization requirements, Counterforce Health provides specialized support in turning insurance denials into targeted, evidence-backed appeals by analyzing denial letters, plan policies, and clinical notes to draft compelling rebuttals aligned with each payer's specific criteria.

Sources and Further Reading

Disclaimer: This article provides educational information about insurance coverage and is not medical advice. Always consult with your healthcare provider about treatment decisions and work with your insurance company directly for coverage determinations. For assistance with insurance appeals in Illinois, contact the Illinois Department of Insurance at 877-527-9431.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.